免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
开发用于晚期泌尿生殖系统肿瘤患者的 TIL（肿瘤浸润淋巴细胞）疗法的机遇与障碍
英文原题：The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.
查看英文原题
The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
采用TIL（肿瘤浸润淋巴细胞）的过继细胞疗法，是增强免疫治疗的一种非常成功的模式。该疗法已为晚期黑色素瘤患者带来临床获益，并于2024年成为首个获FDA批准的此类免疫治疗方式。数十年前开展的晚期肾细胞癌临床试验未显示显著临床获益，但近期TIL生成流程、细胞操作技术、预处理方案及与免疫检查点抑制剂联合等方面的进展，为重新探索优化TIL疗法治疗泌尿生殖系统癌症带来新希望。当前TIL疗法在细胞制备、流程优化和递送方法方面取得进展，有望改善其治疗晚期泌尿生殖系统恶性肿瘤的安全性和疗效。此外，创新联合方案和新策略可能提升TIL疗法的临床可行性，值得在泌尿生殖系统癌症患者临床试验中评估。
展开英文摘要原文
Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024.
Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers.
The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies.
Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.
论文信息
- 作者
- Potez M、Roman Souza G、Spiess PE、Pilon-Thomas S、Chahoud J
- 第一作者单位
- Immuno-Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.United States
- 通讯作者单位
- Genitourinary Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Jad.chahoud@moffitt.org.United States
- 文献类型
- 综述
- 期刊
- Nature reviews. Urology2026 Mar
- 原文标识
- PubMed 41006825 · DOI 10.1038/s41585-025-01088-6